{"id":"mk-2206","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01783171","NCT01776008","NCT01245205","NCT01260701","NCT01147211","NCT01248247","NCT01240941","NCT01235897","NCT01425879","NCT01714128","NCT01307631","NCT01253447","NCT01243762","NCT01231919","NCT01481129","NCT01249105","NCT01306045","NCT01604772","NCT01071018","NCT01802320","NCT01658943","NCT01186705","NCT01370070","NCT01295632","NCT01369849","NCT00963547","NCT01169649","NCT01239355","NCT01344031","NCT01319539","NCT01240928","NCT01281163","NCT01263145","NCT01480154","NCT01042379","NCT01294306","NCT01277757","NCT01239342","NCT01349933","NCT01021748","NCT01283035","NCT01258998","NCT01859182","NCT01519427","NCT01333475","NCT01466868","NCT01705340","NCT00670488","NCT00848718","NCT01251861"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2011","type":"neutral","milestone":"Phase 1 Initiated","description":"A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Ad — Locally Advanced, Metastatic Solid Tumors"},{"date":"2013","type":"negative","milestone":"Phase 2 Initiated","description":"MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy — Adult Hepatocellular Carcinoma. Trial terminated early."}],"aiSummary":"MK-2206 is an AKT inhibitor evaluated in clinical trials for Non-Small Cell Lung Cancer and Recurrent Nasopharyngeal Carcinoma, often in combination with other agents. No FDA-approved indication is listed in the provided text.","brandName":"MK-2206","companyId":"unknown","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"The provided text does not contain a plain-English mechanism description. It only lists clinical trial summaries involving MK-2206 in combination with gefitinib, anastrozole, or fulvestrant for certain cancers.","oneSentence":"MK-2206 is an investigational AKT inhibitor studied in lung cancer and nasopharyngeal carcinoma trials, typically combined with other drugs.","technicalDetail":"The provided source text does not specify molecular targets, pathways, or selectivity details for MK-2206. It only references the drug name in the context of combination clinical trials."},"commercial":null,"references":[],"biosimilars":[],"companyName":"","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"MK-2206","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01783171","phase":"Phase 1","title":"A Phase I Trial of Dinaciclib (SCH727965) and MK-2206 in Metastatic Pancreatic Cancer With an Expansion Cohort in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":42,"indication":"Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma","completionDate":"2016-07-12"},{"nctId":"NCT01776008","phase":"Phase 2","title":"A Phase II Trial of Neoadjuvant MK-2206 in Combination With Either Anastrozole if Postmenopausal or Anastrozole and Goserelin if Premenopausal in Women With Clinical Stage 2 or 3 PIK3CA Mutant Estroge","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":16,"indication":"Estrogen Receptor Positive, HER2/Neu Negative","completionDate":"2015-05-05"},{"nctId":"NCT01245205","phase":"Phase 1","title":"A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-Expansion in Advanced HER2+ Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":28,"indication":"HER2-positive Breast Cancer, Male Breast Cancer","completionDate":""},{"nctId":"NCT01260701","phase":"Phase 2","title":"A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":75,"indication":"Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma","completionDate":"2015-07"},{"nctId":"NCT01147211","phase":"Phase 1","title":"A Phase I Dose Defining Study For MK-2206 Combined With Gefitinib In NSCLC Population Enriched With EGFR Mutation","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":21,"indication":"Non Small Cell Lung Cancer","completionDate":"2013-12"},{"nctId":"NCT01248247","phase":"Phase 2","title":"BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":334,"indication":"Lung Cancer","completionDate":"2020-11-30"},{"nctId":"NCT01240941","phase":"Phase 2","title":"Phase II Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor Positive Breast Cancer","status":"WITHDRAWN","sponsor":"Vanderbilt-Ingram Cancer Center","isPivotal":false,"enrollment":0,"indication":"Metastatic Breast Cancer","completionDate":"2012-12"},{"nctId":"NCT01235897","phase":"Phase 1","title":"A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab","status":"COMPLETED","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":17,"indication":"Advanced Solid Tumors, Tumors","completionDate":"2013-11"},{"nctId":"NCT01425879","phase":"Phase 2","title":"A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":8,"indication":"Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma","completionDate":"2014-05"},{"nctId":"NCT01714128","phase":"NA","title":"Positron Emission Tomography (PET) With 18F-Fluoroestradiol (FES) as a Predictor of Response in Patients With Breast Cancer Scheduled to be Treated With MK-2206 in Combination With Either an Aromatase","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":0,"indication":"Breast Cancer","completionDate":"2015-12"},{"nctId":"NCT01307631","phase":"Phase 2","title":"A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":37,"indication":"Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma","completionDate":"2015-09-18"},{"nctId":"NCT01253447","phase":"Phase 2","title":"A Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients With Relapsed Refractory Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":19,"indication":"Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","completionDate":"2014-04"},{"nctId":"NCT01243762","phase":"Phase 1","title":"Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":47,"indication":"Neoplasms Malignant","completionDate":"2013-03-25"},{"nctId":"NCT01231919","phase":"Phase 1","title":"A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":45,"indication":"Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage","completionDate":""},{"nctId":"NCT01481129","phase":"Phase 2","title":"A Phase 2 Study of MK-2206 in Patients With Relapsed or Refractory Diffuse Large-B Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":22,"indication":"Diffuse Large B Cell Lymphoma","completionDate":"2014-06"},{"nctId":"NCT01249105","phase":"Phase 2","title":"A Phase II Study of MK-2206 for Recurrent Malignant Glioma","status":"WITHDRAWN","sponsor":"Dana-Farber Cancer Institute","isPivotal":false,"enrollment":0,"indication":"Malignant Glioma","completionDate":""},{"nctId":"NCT01306045","phase":"Phase 2","title":"Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":647,"indication":"Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung","completionDate":"2024-07-17"},{"nctId":"NCT01604772","phase":"Phase 2","title":"A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":16,"indication":"Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma","completionDate":"2014-11-22"},{"nctId":"NCT01071018","phase":"Phase 1","title":"A Phase I Study of MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":24,"indication":"Solid Tumors","completionDate":"2011-09"},{"nctId":"NCT01802320","phase":"Phase 2","title":"A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":18,"indication":"Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma","completionDate":"2015-08-05"},{"nctId":"NCT01658943","phase":"Phase 2","title":"Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":137,"indication":"Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma","completionDate":"2015-06"},{"nctId":"NCT01186705","phase":"Phase 2","title":"A Phase II Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":1,"indication":"Colon Cancer, Rectal Cancer","completionDate":"2011-08"},{"nctId":"NCT01370070","phase":"Phase 2","title":"Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","isPivotal":false,"enrollment":12,"indication":"Recurrent Nasopharyngeal Carcinoma","completionDate":"2017-01"},{"nctId":"NCT01295632","phase":"Phase 1","title":"Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":65,"indication":"Advanced Cancer","completionDate":"2015-08"},{"nctId":"NCT01369849","phase":"Phase 1","title":"Phase I/II Study of the Combination of Bendamustine, Rituximab and MK-2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":15,"indication":"Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma","completionDate":"2014-02"},{"nctId":"NCT00963547","phase":"Phase 1","title":"A Phase I Investigation of the Combination of MK-2206, Trastuzumab and Lapatinib in HER2+ Solid Tumors","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":33,"indication":"Advanced Solid Tumors, Breast Cancer","completionDate":"2011-12-22"},{"nctId":"NCT01169649","phase":"Phase 2","title":"A Phase II Clinical and Translational Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":11,"indication":"PANCREAS, Neuroendocrine","completionDate":"2014-02"},{"nctId":"NCT01239355","phase":"Phase 2","title":"A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":15,"indication":"Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma","completionDate":"2013-02"},{"nctId":"NCT01344031","phase":"Phase 1","title":"A Phase 1 Trial of MK-2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":31,"indication":"Estrogen Receptor Positive, Invasive Breast Carcinoma","completionDate":""},{"nctId":"NCT01319539","phase":"Phase 2","title":"Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":12,"indication":"Estrogen Receptor Negative, Estrogen Receptor Positive","completionDate":"2013-07"},{"nctId":"NCT01240928","phase":"Phase 1","title":"A Phase Ib Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer","status":"WITHDRAWN","sponsor":"Vanderbilt-Ingram Cancer Center","isPivotal":false,"enrollment":0,"indication":"Metastatic Breast Cancer","completionDate":""},{"nctId":"NCT01281163","phase":"Phase 1","title":"A Phase 1b Dose-Escalation Study of the AKT Inhibitor MK-2206 (NSC# 749607) Plus Lapatinib (NSC# 727989) Administered in Patients With HER2 Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":4,"indication":"Estrogen Receptor Negative, Estrogen Receptor Positive","completionDate":"2013-12"},{"nctId":"NCT01263145","phase":"Phase 1","title":"Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanc","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":34,"indication":"Adult Solid Neoplasm, Recurrent Breast Carcinoma","completionDate":"2012-10-19"},{"nctId":"NCT01480154","phase":"Phase 1","title":"A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":62,"indication":"Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7","completionDate":"2027-03-31"},{"nctId":"NCT01042379","phase":"Phase 2","title":"I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","isPivotal":false,"enrollment":5000,"indication":"Breast Neoplasms, Breast Cancer","completionDate":"2031-12"},{"nctId":"NCT01294306","phase":"Phase 2","title":"Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Er","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":80,"indication":"Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma","completionDate":"2015-08"},{"nctId":"NCT01277757","phase":"Phase 2","title":"Phase II Trial of AKT Inhibitor MK2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation, or an AKT Mutation, and/or PTEN Loss/PTEN Mutation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":30,"indication":"Recurrent Breast Carcinoma, Stage IIIB Breast Cancer","completionDate":"2014-08"},{"nctId":"NCT01239342","phase":"Phase 2","title":"A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":43,"indication":"Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma","completionDate":"2018-09-19"},{"nctId":"NCT01349933","phase":"Phase 2","title":"Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":21,"indication":"Recurrent Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx","completionDate":"2013-10"},{"nctId":"NCT01021748","phase":"Phase 1","title":"A Phase I Study of Oral MK-2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":63,"indication":"Locally Advanced or Metastatic Solid Tumors","completionDate":"2014-07-16"},{"nctId":"NCT01283035","phase":"Phase 2","title":"A Phase II Study of MK-2206 in the Treatment of Recurrent High-Grade Serous Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":6,"indication":"Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma","completionDate":"2014-12"},{"nctId":"NCT01258998","phase":"Phase 2","title":"Phase II Study of MK-2206 in Patients With Relapsed Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":60,"indication":"Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma","completionDate":"2015-08"},{"nctId":"NCT01859182","phase":"Phase 2","title":"A Multicenter Phase II Study of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Patients With Refractory Advanced Biliary Cancers","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":0,"indication":"Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder","completionDate":"2013-05"},{"nctId":"NCT01519427","phase":"Phase 2","title":"A Phase II Trial of MAP Kinase Inhibition With AZD6244 Hydrogen Sulfate in Combination With MK-2206 (Akt Inhibitor) in Patients With BRAF V600-Mutant Advanced Melanoma Whose Disease Has Progressed on ","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":2,"indication":"Recurrent Melanoma, Stage IIIA Melanoma","completionDate":"2013-05"},{"nctId":"NCT01333475","phase":"Phase 2","title":"Pilot Study of the Combination of MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor, in Patients With Advanced Colorectal Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":21,"indication":"Colorectal Neoplasms","completionDate":"2014-09"},{"nctId":"NCT01466868","phase":"Phase 2","title":"A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma","status":"TERMINATED","sponsor":"Centre Leon Berard","isPivotal":false,"enrollment":22,"indication":"Diffuse Large B Cell Lymphoma","completionDate":"2014-06"},{"nctId":"NCT01705340","phase":"Phase 1","title":"A Phase I Study of MK-2206 in Combination With Trastuzumab and Lapatinib in HER2-Positive Breast and Gastric Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":60,"indication":"Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer","completionDate":""},{"nctId":"NCT00670488","phase":"Phase 1","title":"A Phase I Dose Escalation Study of Oral MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":104,"indication":"Locally Advanced Tumors, Metastatic Solid Tumors","completionDate":"2011-07-11"},{"nctId":"NCT00848718","phase":"Phase 1","title":"A Phase I Dose Escalation Study of MK-2206 in Combination With Standard Doses of Selected Chemotherapies or Targeted Agents in Patients With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":77,"indication":"Locally Advanced, Metastatic Solid Tumors","completionDate":"2012-05-17"},{"nctId":"NCT01251861","phase":"Phase 2","title":"Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":108,"indication":"Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7","completionDate":"2026-03-18"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":8,"withResults":7},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}